Cyclophosphamide-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•Agonists•ScreeningLibrarieswww.MedChemECyclophosphamideCat.No.:HY-17420CASNo.:50-18-0分⼦式:C₇H₁₅Cl₂N₂O₂P分⼦量:261.09作⽤靶点:DNAAlkylator/Crosslinker作⽤通路:CellCycle/DNADamage储存⽅式:4°C,protectfromlight*该产品在溶液状态不稳定，建议您现⽤现配，即刻使⽤。溶解性数据体外实验DMSO:≥38mg/mL(145.54mM)扫描⼆维码，H2O:33.33mg/mL(127.66mM;Needultrasonic)运⽤溶解⽅案计算器*"≥"meanssoluble,butsaturationunknown.获得适合您实验体系的溶解⽅案MassSolvent1mg5mg10mgConcentration制备储备液1mM3.8301mL19.1505mL38.3010mL5mM0.7660mL3.8301mL7.6602mL10mM0.3830mL1.9150mL3.8301mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现⽤现配，即刻使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶1.请依序添加每种溶剂：10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.5mg/mL(9.58mM);Clearsolution此⽅案可获得≥2.5mg/mL(9.58mM，饱和度未知)的澄溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。1/3www.MedChemEwww.MedChemE2.请依序添加每种溶剂：10%DMSO90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(9.58mM);Clearsolution此⽅案可获得≥2.5mg/mL(9.58mM，饱和度未知)的澄溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶3.液中，混合均匀。请依序添加每种溶剂：10%DMSO90%cornoilSolubility:≥2.5mg/mL(9.58mM);Clearsolution此⽅案可获得≥2.5mg/mL(9.58mM，饱和度未知)的澄溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。4.以1mL⼯作液为例，取100μL25.0mg/mL的澄请依序添加每种溶剂：PBSDMSO储备液加到900μL⽟⽶油中，混合均匀。Solubility:50mg/mL(191.50mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY⽣物活性Cyclophosphamide⼀种合成的DNAAlkylator，在化学上与氮芥类有关，具有抗肿瘤及免疫抑制活性。IC50&TargetDNAAlkylator[1]体外研究Cyclophosphamideinducesoutermembraneblebbing,leadstoDNAfragmentation,asrevealedbyTUNELstainingoffree3'-OHDNAends,andinducescleavageofthecaspase3andcaspase7substratePARPin9L/P450cells.Bcl-2expressionfullyblockstheactivationofbothinitiatorcaspasesaswellastheeffectorcaspase3incellstreatedwithactivatedCyclophosphamide.Bcl-2inhibitsthecytotoxiceffectsbutnotthecytostaticeffectsofactivatedCyclophosphamide[1].CyclophosphamideinhibitstheAChEreversiblywithanIC50of511μM[2].Carbontetrachloridedoesnotaffectthedirectcytotoxicityofcyclophosphamideor4-hydroxycyclophosphamidetocellsinculture[3].体内研究Cyclophosphamide(injectedi.p.;2mg/mousein0.1mLPBS,inC3HmicebearingSW1tumors)increasesthepercentageofcellsthatstainedforCD3,CD4orCD8inbothspleensandtumors[4].AnimalModel:Sixtoeight-weekoldfemaleC3H/HeNmicebearingSW1tumors[4]Dosage:2mg/mouseAdministration:Injectedi.p.;2mg/mousein0.1mLPBS;4daysResult:IncreasedthepercentageofcellsthatstainedforCD3,CD4orCD8inbothspleensandtumors.户使⽤本产品发表的科研⽂献•NatCommun.2021Jan4;12(1):20.•CellDeathDis.2020Nov12;11(11):976.•BiochemPharmacol.2021Jan;183:114340.2/3www.MedChemEwww.MedChemE•JMolMed(Berl).2019Aug;97(8):1183-1193.•LifeSci.2020Aug1;254:117590.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].SchwartzPS,etal.Cyclophosphamideinducescaspase9-dependentapoptosisin9Ltumorcells.MolPharmacol.2001Dec;60(6):1268-1279.[2].al-JafariAA,etal.Inhibitionofhumanacetylcholinesterasebycyclophosphamide.Toxicology.1995Jan19;96(1):1-6.[3].HarrisRN,etal.Carbontetrachloride-inducedincreaseintheantitumoractivityofcyclophosphamideinmice:apharmacokineticstudy.CancerChemotherPharmacol.1984;12(3):167-72.[4].LiuP,etal.Administrationofcyclophosphamidechangestheimmuneprofileoftumor-bearingmice.JImmunother.2010Jan;33(1):53-9.McePdfHeight关注MCE中国公众号，

获取前沿资讯、最新活动和

实⽤科研⼯具MedChemExpress(MCE)只为有资质的科研机构、医药企业基于